Assessing Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Dominant Hepatic Cysts: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Trial Profile

Assessing Efficacy of Combining Pasireotide With Aspiration Sclerotherapy to Improve Volume Reduction of Dominant Hepatic Cysts: a Randomized, Double-blind, Placebo-controlled Clinical Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2016

At a glance

  • Drugs Pasireotide (Primary)
  • Indications Cysts; Polycystic liver disease
  • Focus Therapeutic Use
  • Acronyms Sclerocyst
  • Most Recent Events

    • 19 Oct 2016 Results assessing efficacy of Pasireotide in cyst reduction presented at the 24th United European Gastroenterology Week.
    • 03 May 2016 Status changed from recruiting to completed.
    • 09 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 May 2016 as reporetd by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top